Table 1.
Baseline characteristics of patients.
| Cohort 1: |
Cohort 2: |
|
|---|---|---|
| Patients diagnosed with osteoporosisa |
Patients initiating bisphosphonatesa |
|
| (N = 18,813) | (N = 6040) | |
| Age at the index date, mean (SD)b | 71.4 (9.2) | 73.3 (8.6) |
| Age distribution | ||
| 55–64 | 4751 (25.3) | 1021 (16.9) |
| 65–74 | 6902 (36.7) | 2170 (35.9) |
| 75–84 | 5578 (29.7) | 2303 (38.1) |
| ≥ 85 | 1582 (8.4) | 546 (9.0) |
| Pre-index medication useb | ||
| Gastroprotective agents | 3408 (18.1) | 1746 (28.9) |
| Proton pump inhibitors | 2617 (13.9) | 1500 (24.8) |
| H2 receptor antagonists | 949 (5.0) | 342 (5.7) |
| Cytoprotectants | 54 (0.3) | 18 (0.3) |
| NSAIDs | 6644 (35.3) | 2769 (45.8) |
| Glucocorticoids | 3170 (16.9) | 1399 (23.2) |
| Estrogen | – | 107 (1.8) |
| Pre-index GI eventsb | 2601 (13.8) | 1033 (17.1) |
| Pre-index OP-related fracturesb | 663 (3.5) | 554 (9.2) |
| OP-related fractures by site | ||
| Hip | 158 (0.8) | 138 (2.3) |
| Vertebral | 241 (1.3) | 317 (5.3) |
| Non-vertebral | 279 (1.5) | 130 (2.2) |
| Deyo-Charlson comorbidity index, mean (SD) | 0.79 (1.11) | 0.87 (1.16) |
| Common OP-related comorbiditiesc | ||
| Hypertension | 8053 (42.8) | – |
| Depression | 2228 (11.8) | – |
| Diabetes | 1335 (7.1) | – |
| GI mucositis & urination problems | 687 (3.7) | – |
| Chronic inflammatory joint disease | 546 (2.9) | – |
| Fatigue | 328 (1.7) | – |
| Chronic kidney disease | 119 (0.6) | – |
| Chronic inflammatory bowel disease | 88 (0.5) | – |
| Hyperparathyroidism | 24 (0.1) | – |
| Vitamin D deficiency | 6 (0.03) | – |
| Celiac disease | 3 (0.02) | – |
GI, gastrointestinal; NSAIDs, non-steroidal anti-inflammatory drugs; OP, osteoporosis; SD, standard deviation.
a
Values are presented as N (%) unless indicated otherwise.
b
The index date was the date of osteoporosis diagnosis for cohort 1 and the date of initiation of an oral bisphosphonate for cohort 2.
c
Comorbidities were not collected for cohort 2.